논문KCI 등재
Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”Do Hyun Park, Woo Hyun Paik대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK- 660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”Nilanga Nishad대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”Atsumasa Komori대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trialCe Hwan Park, Do Hyun Park, Gunn Huh, Hee Jin Kim, Heon Se Jeong, Joo Kyung Park, Moon Jae Chung, Sang Hyub Lee, Woo Hyun Paik대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”Chuan Liu, Gao-Jun Teng, Hong You, Ling Yang, Xiaolong Qi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호The More, the Better? Predicting Prognosis in Primary Biliary CholangitisBo Hyun Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제6호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12Letter to the editor on “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”Ruiyun Guo, Yuqian Liu, Jun Mapp. 13-15